Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization

Launched by UNIVERSITY HOSPITAL, ROUEN · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the role of certain immune cells, called memory B lymphocytes, in kidney transplant patients who have developed antibodies against HLA antigens, which are proteins found on the surface of cells. These antibodies can cause the body to reject a transplanted kidney. The researchers want to better understand how these memory B cells behave and how they might affect the success of a transplant. By learning more about these cells, the goal is to improve ways to prevent rejection and ensure better outcomes for transplant patients.

To participate in the study, you must be at least 18 years old, be a patient at Rouen University Hospital's Nephrology and Kidney Transplantation Department, and be on the national kidney transplant waiting list. You should also have specific antibodies against HLA identified during a recent screening. Participants can expect to have their blood samples analyzed to help researchers gain insights into their immune responses. It's important to note that individuals who have certain recent medical treatments, active infections, or specific legal statuses may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Rouen University Hospital patient monitored in the Nephrology and Kidney Transplantation Department, registered on the national kidney transplant waiting list
• • Carrier of HLA antibodies, including at least anti-HLA2, identified during the last screening
• • Notion of classic immune-promoting events including at least one previous transplant or pregnancy, or absence of a known immune-promoting event (naïve patient group)
• • Incompatible graft rate (IGR)
• • IGR ≥ 85% (hyperimmunized patient group with anti-HLA polyreactivity) or
• • IGR between 50% and 85% (immunized patient group with a more restricted repertoire of HLA reactivities) or
• • IGR \< 50% (naïve patient group with no known history of immune-promoting events)
• • Person who has read and understood the information letter and does not object Not participating in the study
• • Affiliation to a social security scheme
• Exclusion Criteria:
• • Patients who have received rituximab in the previous year (B-cell depleting therapy)
• • Patients undergoing an HLA desensitization protocol using plasmapheresis and/or rituximab
• • Patients with an active infection
• • Persons deprived of their liberty by an administrative or judicial decision or persons placed under judicial protection/guardianship or curatorship